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Abstract: Oral vancomycin is often considered the drug of choice for
severe Clostridium di⁄cile-associated disease due to both its e⁄cacy
and pharmacokinetics.The potential for absorption is not well
described in patients with impaired gastrointestinal (GI) mucosa.We
describe a case of signi¢cant and potentially toxic absorption of oral
vancomycin in a peripheral blood stem cell transplant patient with
grade IVgraft-versus-host disease (GVHD) of the GI tract. In patients
with GI GVHD clinicians need to be aware of the potential for oral











































































































Oral vancomycin is a routinely used agent for the treatment
of Clostridium di⁄cile-associated diarrhea (CDAD). Na-
tional experts recommend oral vancomycin for severe
CDAD based on selected literature that supports an in-
crease in e⁄cacy over metronidazole (1) and the fact that
the drug reaches concentrations  1000 times the mini-
mum inhibitory concentration of the organism at the site
of actionwithout signi¢cant systemic absorption (2).These
recommendations and the emergence of the more virulent,
NAP-1 strain have led to a more widespread use of oral van-
comycin in patient populations where both e⁄cacy and the
potential for systemic absorption have not been well stud-
ied.We report a case of signi¢cant and potentially toxic ab-
sorption of oral vancomycin in a peripheral blood stem cell
transplant (PBSCT) recipient with severe gastrointestinal
(GI) graft-versus-host disease (GVHD).
Case report
A 62-year-old male with myelodysplastic syndrome under-
went a 10/10 HLA-matched unrelated donor PBSCT that
was complicated by grade I acute GI GVHD, cytomegalovi-
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rus reactivation, and human herpesvirus-6 encephalopa-
thy. On day 1 200 after transplant, he was readmitted with
4^6 episodes of diarrhea daily (average stool output 1.5^
2 L/day) and he was found to have C. di⁄cile, as well as
grade IV GI GVHD. The computed tomography ¢ndings
demonstrated congestion in the mucosa throughout the co-
lon and the histopathologic ¢ndings were most consistent
with severe (grade IV) GVHD.
However, the patient had several risk factors for C. di⁄-
cile, including recent antibiotic use, acid suppression ther-
apy, recent prolonged hospitalization, advanced age, and
severe underlying illness due to GVHD and immunosup-
pression.The white blood cell count was within the normal
range and pseudomembranes were not present on endos-
copy; nevertheless, the diagnosis of C. di⁄cile colitis was
made on the basis of clinical ¢ndings in conjunction with
a positive stool toxin assay (ProSpecTsC. di⁄cile toxinTox-
in A/B Microplate Assay; Remel Inc., Lenexa, Kansas,
USA). Oral vancomycin 250 mg solutionwas initiated every
6 h along with rifaximin 200 mg 3 times a day for presumed
severe CDADwhile methylprednisolone 2 mg/kg/day intra-
venously was started for GVHD. Throughout the patient’s
course he also received 5 days of mycophenolate, 17 days of
cyclosporine, 13 days of oral budesonide, and 4 days of sir-
olimus.The patient did not receive intravenous vancomycin
during his hospitalization.
The patient’s serum creatinine began to increase on hos-
pital day19 and, as a result, a vancomycin level was ordered
and found to be 26.4 mg/L.The vancomycinwas held for the
next 4 days, while rifaximin was continued, with a subse-
quent return to the patient’s baseline renal function (serum
creatinine 1.5 mg/dL) and a corresponding decrease in van-
comycin concentration (5.9 mg/L). Table 1 displays his van-
comycin doses and levels, as well as his serum creatinine
levels.
On hospital day 25, oral vancomycinwas restarted at a re-
duced dose of 125 mg every 6 h. On day 28 of hospitalization,
the vancomycin dose was again increased to 250 mg every
6 h because the patient was still having severe diarrhea. Six
days after the dosage increase, a second rise in serum creati-
nine was observed with a corresponding vancomycin level
of 13.3 mg/L.The patient went on to develop bacteremiawith
vancomycin-resistant Enterococcus faecium and Candida
glabrata, and he died on hospital day 35.
Discussion
Case reports (Table 2) describe the signi¢cant accumula-
tion of oral vancomycin in selected patients with renal in-
su⁄ciency (3^7 ), and a more recent case report (8) showed
signi¢cant systemic vancomycin levels in a patient with se-
vere C. di⁄cile disease with normal renal function. The
package insert forVancocins pulvules (Eli Lilly, Indianap-
olis, Indiana, USA) states that ‘signi¢cant absorption may
infrequently occur in patients with C. di⁄cile-induced pseu-
domembranous colitis, and, in the presence of renal impair-
ment, the possibility of accumulation exists’ (2). However,
systemic absorption of oral vancomycin has not been re-
ported to our knowledge in a patient with severe GI GVHD.
We present a case of signi¢cant oral vancomycin absorp-
tion in a PBSCTpatient with severe GI GVHD. Based on the
timing of the vancomycin levels and patient’s underlying
illness, it is di⁄cult to ascertainwhether high levels of van-
comycin led to renal insu⁄ciency, or if it was the impaired
renal function that led to the accumulation of vancomycin.
Regardless of the exact mechanism, this patient had both
clinically relevant and potentially toxic vancomycin con-













1 N/A N/A 1.5 1
4^17 250 N/A 1.0^1.5 N/A
18 250 N/A 1.3 1




21 Held 22.1, 22.6 2.0 N/A
22 Held 15.1 1.8 N/A
23 Held N/A 1.6 N/A
24 Held 8.6 1.5 N/A
25 1251 5.9 1.4 N/A
26 1251 N/A 1.3 N/A
27 1251 5.0 1.4 N/A
28 2501 4.4 1.4 N/A
29 2502 N/A 1.5 N/A
30 2503 3.7 1.5 N/A
31^33 250 N/A 1.5^2.2 N/A
34 Held 13.3 2.6 N/A




1Patient received 2 doses of vancomycin.
2Patient received 1 dose of vancomycin.
3Patient received 3 doses of vancomycin.
C(1), concentration at 1h after oral dose; C(tr), trough concentration;
N/A, not available.
Table1
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centrations, despite never receiving intravenous van-
comycin.These data are particularly interesting in the light
of 2 recent reports showing patients having systemic hy-
persensitivity-type adverse drug reactions attributed to
oral vancomycin therapy (10, 11).
The diagnosis of CDAD and response to treatment can be
challenging in this patient population. GI GVHD is com-
mon and is graded based on daily stool volume with grade
I disease de¢ned as stool output4500 mL/day, grade II as
41000 mL/day, grade III as 41500 mL/day, and grade IV
as 42000 mL/day (12). Symptoms of GVHD and CDAD
both often include fever and leukocytosis. Because
the symptoms are similar, it is often di⁄cult to ascertain
the severity of the CDAD infection versus the GVHD. Given
these diagnostic limitations, empirical treatment for severe
CDAD with oral vancomycin is not uncommon in the
setting of GI GVHD. As demonstrated in this report, loss
of GI integrity may lead to increased bioavailability,
and therefore, the potential for signi¢cant accumulation of
vancomycin, and possible adverse e¡ects. The additive ne-
phrotoxicity based on drug interactions with other medica-
tions often co-administered for transplant, such as
calcineurin inhibitors, sirolimus, and foscarnet, among
others, would be of additional concern. Our patient was
on multiple concomitant nephrotoxins.While the concen-
tration of these agents was not considered toxic (sirolimus
levels were undetectable and cyclosporine levels remained
o100 ng/mL), additive toxicity with vancomycin cannot be
ruled out.
We are not able to ascertain the relative contribution of
CDAD or GI GVHD to the absorption of vancomycin, but
the fact that the systemic level was high after 19 days of
treatment (a time course during which most patients with
CDAD would have improved) suggests that GI GVHD con-
tributed to systemic absorption. If, as our case report sug-
gests, oral vancomycin, which is generally considered to be
nonabsorbable, can be absorbed in instances of severe
GVHD, with or without severe CDAD, as a result of im-
paired intestinal integrity, might other non-absorbable
drugs also be absorbed? Two agents that are commonly
used in this patient population include rifaximin and bu-
desonide. A combination of oral vancomycin and rifaximin
has also been used to treat recurrent or persistent CDAD
(13). Absorption of rifaximin could potentially lead to met-
abolic drug interaction with drugs such as azole antifun-
gals or calcineurin inhibitors; and increased levels of
systemic steroids could increase the risk of infection.While
this warrants further investigation, it is essential to be
aware of the potential for absorption of these ‘non-absorb-
able’drugs in patients with GI GVHD.






dose (mg p.o.q6h) Serum creatinine Level (mg/L) References
1 62 M 500 HD 11.3^20.3 (3)
1 32 M 250 HD 5.8 (4)
1 45 M 250 HD 2.6 (4)
1 45 M 500 HD 11^13 (4)
1 45 M 125 HD 3.4 (4)
1 28 M 500 HD 0.7^9.8 (4)
10 14^81 M/F 125 Ranged from normal
to severe impairment
4/11 patients with detectable
(1.0^3.1) levels
(5)
10 N/A 500 N/A 1 patient with level of 3.9,
all others 1
(6)
12 N/A 500 Normal 8 had undetectable levels (7)
54 F 500 Normal 2.4 (7)
89 M 500 2.3 1.2 (7)
71 M 500 1.2 1.3 (7)
66 F 500 HD 5.1 (7)
1 77 F 125^5001
vancomycin enemas
1.0 6.3^7.9 (8)
HD, patient on hemodialysis.
Table 2
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The third question raised is the seemingly dose-
dependent absorption that is noted in all cases where sig-
ni¢cant absorption has been seen (3^5). A dose of 125 mg
every 6 h has been found to be equivalent to 500 mg every
6 h for the treatment of CDAD (9). This would imply
no added bene¢t in utilizing the higher dose. The decision
to use a 500 mg dose over a 125 mg dose in this patient pop-
ulation could increase the risk of accumulation and poten-
tial toxicity.
The very conditions for which oral vancomycin is
indicatedçthat is, severe disease marked by severe in£am-
mation, potential renal insu⁄ciency, and high stool out-
putsçmay, in fact, be the very situations where oral
absorption might be an issue. In treating patients with GI
GVHD, clinicians need to be aware of the potential for oral
absorption and, in select cases, monitoring of levels may be
appropriate.
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